#USA #New York #Class Action #Rosen Law Firm #Altimmune

Overview

Rosen Law Firm, a leading player in investor rights advocacy, has put out a call for shareholders of Altimmune, Inc. (NASDAQ: ALT) to connect with their office regarding entitlements and options following a recent class action lawsuit. The class action pertains to securities bought between August 10, 2023, and June 25, 2025, aiming to protect the rights of those impacted by the alleged shortcomings of the company.

Background on Altimmune

Altimmune, Inc., a clinical-stage biopharmaceutical company, specializes in developing therapies to treat various infectious diseases, respiratory conditions, and other medical issues. Despite its promising portfolio, the company recently faced scrutiny concerning the results of its IMPACT Phase 2b MASH trial, which was expected to yield significant data on fibrosis reduction. According to the lawsuit, Altimmune allegedly misled investors regarding its interim findings during the trials, leading many shareholders to hold inflated expectations based on misrepresented information.

Details of the Class Action

The class action complaint indicates that throughout the designated Class Period, the defendants in the lawsuit created a misleading portrayal of the data regarding Altimmune's clinical trials. Notably, the trial's primary endpoint concerning fibrosis reduction did not meet the required statistical significance. Altimmune had widely touted positive expected outcomes from these trials, while downplaying or failing to disclose increasing response rates within the placebo group, which they should have recognized would tarnish overall results. This misrepresentation substantializes claims that investors suffered financial losses once the actual trial results became public.

Actions for Shareholders

As a shareholder of Altimmune, it’s crucial to act quickly if you believe you have been adversely affected by the mismanagement of information surrounding these trials. Affected investors are encouraged to participate in this class action by filing a claim through a dedicated portal. This move allows you to express interest in being a lead plaintiff and potentially recover losses without bearing any upfront legal fees, as the arrangement operates on a contingency fee basis.

For more detailed information on how to join the class action, investors can visit Rosen Law Firm’s submission page or directly contact Phillip Kim, Esq. at 866-767-3653. Alternatively, you can streamline the inquiry process by reaching out via email at [email protected].

Conclusion

Rosen Law Firm reassures potential class members that while the legal journey may seem daunting, joining the class action opens pathways for accountability and potential recovery of losses incurred during the Class Period. It reinforces the firm's commitment to safeguarding investor rights and holding corporations accountable for their corporate disclosures. In these critical times, informed and swift action will be the key for investors impacted by Altimmune’s clinical trial results and the ensuing implications.

Stay connected with updates and developments from Rosen Law Firm through their LinkedIn, Twitter, and Facebook profiles.